Improved efficacy of mitochondrial disrupting agents upon inhibition of autophagy in a mouse model of BRCA1-deficient breast cancer
- 3 July 2018
- journal article
- research article
- Published by Taylor & Francis in Autophagy
- Vol. 14 (7) , 1214-1225
Abstract
Breast cancer is a heterogeneous disease, and stratification of patients is fundamental to the success of treatment modalities. Breast tumors deficient in BRCA1 are mostly associated with basal-like breast cancers and targeted therapeutics for this disease subtype are still lacking. In order to address whether macroautophagy/autophagy inhibition will be effective in BRCA1-deficient mammary tumors, we generated mice with conditional deletion of an essential autophagy gene, Rb1cc1, along with Brca1 and Trp53, through utilization of the K14-Cre transgene. We found that Rb1cc1 deletion suppressed tumorigenesis in the BRCA1-deficient model when compared to wild type and heterozygous Rb1cc1 controls. However, in contrast to previous studies in the mouse mammary tumor virus (MMTV)-polyoma middle T antigen (PyMT) model, tumor growth and the distribution of histological subtypes were not affected by loss of RB1CC1. Interestingly, loss of RB1CC1 decreased mitochondrial mass and oxidative respiratory capacity of these tumor cells, along with a decrease in the phosphorylation of MTOR substrates and transcript levels of genes involved in mitochondrial biogenesis. Importantly, we observed an increased sensitivity to mitochondrial disrupting agents upon loss of RB1CC1. Consequently, our data showed that combination of an autophagy inhibitor, spautin-1, along with a mitochondrial complex I inhibitor, metformin, was more effective in limiting oxidative respiratory capacity, colony-forming ability and tumor growth. Altogether, our results indicate that inhibition of autophagy can increase the benefits of metformin treatment in BRCA1-deficient breast cancers.Keywords
Funding Information
- HHS | NIH | National Cancer Institute (CA211066)
This publication has 51 references indexed in Scilit:
- Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cellsOncogene, 2012
- Deconvoluting the context-dependent role for autophagy in cancerNature Reviews Cancer, 2012
- Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesisGenes & Development, 2011
- Genetic Predisposition Directs Breast Cancer Phenotype by Dictating Progenitor Cell FateCell Stem Cell, 2011
- Autophagy facilitates glycolysis during Ras-mediated oncogenic transformationMolecular Biology of the Cell, 2011
- Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong RemissionCancer Research, 2009
- Inactivation of FIP200 Leads to Inflammatory Skin Disorder, but Not Tumorigenesis, in Conditional Knock-out Mouse ModelsJournal of Biological Chemistry, 2009
- Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1 -mutated basal-like breast cancerProceedings of the National Academy of Sciences, 2007
- Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesisGenes & Development, 2007
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003